These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 8544417

  • 21. Thromboxane A2 mediates increased pulmonary microvascular permeability following limb ischemia.
    Klausner JM, Paterson IS, Goldman G, Kobzik L, Valeri CR, Shepro D, Hechtman HB.
    Circ Res; 1989 Jun; 64(6):1178-89. PubMed ID: 2720919
    [Abstract] [Full Text] [Related]

  • 22. Postischemic renal injury is mediated by neutrophils and leukotrienes.
    Klausner JM, Paterson IS, Goldman G, Kobzik L, Rodzen C, Lawrence R, Valeri CR, Shepro D, Hechtman HB.
    Am J Physiol; 1989 May; 256(5 Pt 2):F794-802. PubMed ID: 2541628
    [Abstract] [Full Text] [Related]

  • 23. Thromboxane A2 moderates permeability after limb ischemia.
    Lelcuk S, Alexander F, Valeri CR, Shepro D, Hechtman HB.
    Ann Surg; 1985 Nov; 202(5):642-6. PubMed ID: 3840349
    [Abstract] [Full Text] [Related]

  • 24. In vivo enhancement of platelet activating factor-induced prostacyclin production by OKY-046, a selective inhibitor of thromboxane A2 synthase.
    Davenport NJ, Goldstein RE, Feuerstein GZ.
    J Cardiovasc Pharmacol; 1991 Apr; 17(4):641-6. PubMed ID: 1711633
    [Abstract] [Full Text] [Related]

  • 25. Effects of OKY 046, a thromboxane-synthase inhibitor, on renal function in nonazotemic cirrhotic patients with ascites.
    Gentilini P, Laffi G, Meacci E, La Villa G, Cominelli F, Pinzani M, Buzzelli G.
    Gastroenterology; 1988 Jun; 94(6):1470-7. PubMed ID: 3360268
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Effects of a selective thromboxane synthetase inhibitor OKY-046 on experimental diabetic nephropathy.
    Hora K, Oguchi H, Furukawa T, Hora K, Tokunaga S.
    Nephron; 1990 Jun; 56(3):297-305. PubMed ID: 2077412
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Acute and chronic effects of thromboxane A2 inhibition on the renal hemodynamics in streptozotocin-induced diabetic rats.
    Uriu K, Kaizu K, Hashimoto O, Komine N, Etoh S.
    Kidney Int; 1994 Mar; 45(3):794-802. PubMed ID: 8196281
    [Abstract] [Full Text] [Related]

  • 31. Hemodynamic roles of thromboxane A2 and prostaglandin E2 in glomerulonephritis.
    Stork JE, Dunn MJ.
    J Pharmacol Exp Ther; 1985 Jun; 233(3):672-8. PubMed ID: 3859644
    [Abstract] [Full Text] [Related]

  • 32. Thromboxane synthesis inhibition increases renal prostacyclin and prevents renal disease progression in rats with remnant kidney.
    Zoja C, Perico N, Corna D, Benigni A, Gabanelli M, Morigi M, Bertani T, Remuzzi G.
    J Am Soc Nephrol; 1990 Nov; 1(5):799-807. PubMed ID: 2133429
    [Abstract] [Full Text] [Related]

  • 33. Renal effects of the inhibitor of thromboxane A2-synthetase OKY-046.
    Hatziantoniou C, Papanikolaou N.
    Experientia; 1986 Jun 15; 42(6):613-5. PubMed ID: 3522267
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Role of renomedullary thromboxane A2 in development of doca-salt hypertension.
    Osanai T, Kikuchi T, Yokono Y, Matsumura H, Minami O, Akiba R, Eidoh H, Konta A, Kanazawa T, Onodera K.
    Clin Exp Hypertens A; 1991 Jun 15; 13(2):159-88. PubMed ID: 2065462
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Enalapril in subantihypertensive dosage attenuates kidney proliferation and functional recovery in normotensive ablation nephropathy of the rat.
    Krivosíková Z, Sebeková K, Spustová V, Lajdová I, Dzúrik R.
    Physiol Res; 1999 Jun 15; 48(6):429-35. PubMed ID: 10783907
    [Abstract] [Full Text] [Related]

  • 39. A thromboxane A2 synthase inhibitor, DP-1904, prevents rat renal injury.
    Masumura H, Kunitada S, Irie K, Ashida S, Abe Y.
    Eur J Pharmacol; 1991 Feb 14; 193(3):321-7. PubMed ID: 2055246
    [Abstract] [Full Text] [Related]

  • 40. Assessment of prostacyclin and thromboxane A2 release during reperfusion after global ischemia induced by crystalloid cardioplegia--comparison between warm and cold ischemia.
    Nomura F, Matsuda H, Hirose H, Shirakura R, Ohtani M, Kaneko M, Kawashima Y.
    Eur Surg Res; 1988 Feb 14; 20(2):110-9. PubMed ID: 3292253
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.